Welcome to your Monday Biotech Deal Review for March 4, 2013! The highlights from the past week include Oncolytics’ closing of their$32 million public offering, an update on Paladin’s ongoing share purchase program, and Atrium’s joint venture agreement with Fosum. Get the details on these and the rest of the week’s major biotech news by clicking through.
Top Posts
Biotech Trends
Legal Terms – Please Read
The views expressed here are solely the authors’ and should not be attributed to any of their firms or clients. The material and information provided on this website are for general information only and should not be relied on as legal or business advice or as a legal opinion. The authors make no claims, promises or guarantees about the accuracy, completeness, currency, or adequacy of any information linked or referred to or contained on this blog. No person should act or refrain from acting in reliance on any information found on this blog without first obtaining appropriate professional advice from a consultant or from a lawyer duly licensed to practise law in the relevant province, state, territory or country. These materials do not create a solicitor-client relationship between you and any author. Please note that the authors will not provide free legal, financial or other advice. Please don’t send us any confidential information or questions by email or otherwise because any information sent to us cannot be considered to be privileged or confidential. Note that by accessing, commenting on or linking to the blog, you (like us) are subject to the WordPress Terms of Service. Most images are from Wikimedia Commons or from governments, others link back to commercial sources. If you want us to remove an image, just let us know.
